ClinicalTrials.gg
RecruitingNCT05937789Updated Aug 16, 2024

Early Vitamin D3 Supplementation for Critically Ill Patients

An interventional study of Vitamin D3 and Medium Chain Triglycerides (MCT) in Vitamin D Deficiency and Critical Illness, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 228 studies testing cholecalciferol in Vitamin D Deficiency — 9 open to participants now, 16 under way, 2 of them phase 3. Cholecalciferol · Vitamin D Deficiency.

Planned enrollment
28th of 228
240 · median 72
Started
2024
with 3 others
No phase
113 of 228
6 open now
Primary completion
2026-06
later than 9 of 15 live
Registered
216th of 228
by date

Among the 228 studies testing cholecalciferol in Vitamin D Deficiency, this one is the 28th largest by planned enrollment, is one of 4 that started in 2024, is one of 113 with no phase, reaches primary completion later than 9 of the 15 other live ones, and was the 216th registered.

Vitamin D Deficiency

800 studies on the registry are indexed under Vitamin D Deficiency; 60 are open to participants now.

Browse Vitamin D Deficiency studies →

Open to participants now

9 of the 228 studies testing cholecalciferol in Vitamin D Deficiency are open now, in 7 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About cholecalciferol

Cholecalciferol: first FDA approval 2000 (INFUVITE ADULT), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Vitamin D Deficiency studies recruiting now, 16 (43%) set no upper age limit and 18 (49%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 228 studies testing cholecalciferol in Vitamin D Deficiency, or all of them as a file.
02

Study summary

There are no clear international guidelines for dosing vitamin D based on deficiency severity. Therefore, a new clinical trial is needed to evaluate the benefits of early vitamin D supplementation in maintaining sufficient levels for critically ill patients. The investigators conducted a multicenter clinical trial in Taiwan focusing on vitamin D and critically ill patients. 240 patients with low calcidiol levels will be enrolled and be provided varying supplementation doses to maintain their serum calcidiol levels ≥ 30 ng/mL within 30 days of ICU admission. The serum levels of calcidiol and PTH will be measured on Day 0, Day 7, Day 14 and Day 30 before and after vitamin D supplementation. The results will serve as a valuable reference for intensivists when formulating appropriate vitamin D treatment strategy to maximize clinical benefits for critically ill patients.

Read the detailed description

Recent studies have highlighted a prevalent vitamin D deficiency in critically ill patients, ranging from 26% to 82%. These patients experience longer ICU stays, higher medical expenses, and increased sepsis-related mortality. The investigators conducted a multicenter clinical trial in Taiwan focusing on vitamin D and critically ill patients. In the first phase, the epidemiological investigation found significantly lower serum calcidiol levels of approximately 20.9 ng/mL compared to the normal range of 30-60 ng/mL in ICU patients. The second phase, a randomized control study, preliminarily demonstrated that supplementing 576,000 IU of vitamin D3 in critically ill patients with serum calcidiol levels below 20 ng/mL significantly reduced the risk of multidrug resistant bacterial infections within 30 days. An Austrian trial also showed that adequate vitamin D supplementation lowered in-hospital mortality in severely deficient patients. The importance of vitamin D supplementation for critically ill patients with vitamin D deficiency is evident, as their clinical prognosis is closely related to achieving adequate serum calcidiol levels. However, there are no clear international guidelines for dosing vitamin D based on deficiency severity. Therefore, a new clinical trial is needed to evaluate the benefits of early vitamin D supplementation in maintaining sufficient levels for critically ill patients. The investigators will enroll 240 patients with low calcidiol levels and provide varying supplementation doses to maintain their serum calcidiol levels ≥ 30 ng/mL within 30 days of ICU admission. The serum levels of calcidiol and PTH will be measured on Day 0, Day 7, Day 14 and Day 30 before and after vitamin D supplementation. The results will serve as a valuable reference for intensivists when formulating appropriate vitamin D treatment strategy to maximize clinical benefits for critically ill patients.

03

Conditions studied

  • Vitamin D Deficiency
  • Critical Illness

Keywords

  • vitamin D
  • calcidiol levels
  • critically ill
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18-year-old critically ill patient.
  • ICU admission \< 24 hours.
  • Baseline 25(OH)D levels within 24 hours of ICU admission \< 20 ng/mL.
  • Expected ICU length of stay ≥ 72 hours.

Exclusion criteria

Exclusion Criteria:

  • Hypercalcemia (ie. total serum calcium levels > 2.6 mmol/L).
  • Disorders affecting serum 25(OH)D levels, calcium metabolism, or bone metabolism (eg, parathyroid disease, rickets, or severe cirrhosis [Child C]).
  • Having received high-dose vitamin D3 therapy (ie. > 2,000 IU daily or a single dose of ≥ 10,000 IU) within the past four weeks.
  • Active COVID-19 at ICU admission.
  • Organ transplant.
  • Having had tuberculosis, sarcoidosis or kidney stones within the past year.
  • Having renal dialysis, continuous kidney replacement therapy (CKRT), acute kidney injury (AKI).
  • Having ICU admission within the past three months.
  • Non-native-speaking patients and their families
  • Pregnant women.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Placebo comparator
    Control1

    Participants with serum 25(OH)D levels of 15-19.9 ng/mL, receiving 40 cc. medium-chain triglyceride (MCT) supplement.

    Dietary Supplement: Medium Chain Triglycerides (MCT)

  • Placebo comparator
    Control2

    Participants with serum 25(OH)D levels of 12-14.9 ng/mL, receiving 50 cc. MCT supplement.

    Dietary Supplement: Medium Chain Triglycerides (MCT)

  • Placebo comparator
    Control3

    Participants with serum 25(OH)D levels below 12 ng/mL, receiving 60 cc. MCT supplement.

    Dietary Supplement: Medium Chain Triglycerides (MCT)

  • Experimental
    Vitamin D1

    Participants with serum 25(OH)D levels of 15-19.9 ng/mL, receiving vitamin D3 of 576,000 IU supplement

    Dietary Supplement: Vitamin D3

  • Experimental
    Vitamin D2

    Participants with serum 25(OH)D levels of 12-14.9 ng/mL, receiving vitamin D3 of 720,000 IU supplement

    Dietary Supplement: Vitamin D3

  • Experimental
    Vitamin D3

    Participants with serum 25(OH)D levels below 12 ng/mL, receiving vitamin D3 of 864,000 IU supplement

    Dietary Supplement: Vitamin D3

Interventions

  • Dietary supplementCholecalciferolStudies of CholecalciferolCholecalciferol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dose of vitamin D3 depends on participant's serum 25(OH)D levels, with one sample bottle contains 72,000 IU of vitamin D3; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours

  • Dietary supplementMedium Chain Triglycerides (MCT)

    Dose of MCT depends on participant's serum 25(OH)D levels, with one sample bottle contains 5 cc. of MCT; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours

06

What researchers measure

Primary outcomes

  1. 30-day mortality rate

    30-day mortality rate after intervention with the study samples.

    Time frame: 30 days

Secondary outcomes

  1. 30-day mortality rate of patients who survives >7 days

    30-day mortality rate of patients who survives \>7 days after intervention with the study. samples

    Time frame: 30 days

  2. Length of ICU stay for surviving patients

    Length of ICU stay for surviving patients.

    Time frame: 30 days

  3. Length of hospital stay for surviving patients

    Length of hospital stay for surviving patients.

    Time frame: 30 days

  4. 30-day mortality based on serum 25(OH)D levels on day 7

    Comparison of 30-day mortality between the two treatment groups based on serum 25(OH)D levels on day 7: ≥ 30 ng/mL vs. \< 30 ng/mL.

    Time frame: 30 days

  5. 30-day mortality based on serum 25(OH)D levels on day 30

    Comparison of 30-day mortality between the two treatment groups based on serum 25(OH)D levels on day 30: ≥ 30 ng/mL vs. \< 30 ng/mL.

    Time frame: 30 days

  6. 30-day mortality based on APACHE II scores at ICU 24 hours

    Comparison of 30-day mortality between the three groups based on 24-hour APACHE II scores: \<20, 20-39, and ≥39.

    Time frame: 30 days

  7. Correlation of 25(OH)D increment after vitamin D supplement and body weight

    Correlation between 25(OH)D levels and body weight on day 7 after supplementation in the treatment group.

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jun 2026, 29 months after the start.

Of 167 non-industry interventional studies with no phase under Vitamin D Deficiency, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 29. This study's planned 29 months is above that.

Counting every sponsor, half of 169 studies reached it within 11 months; a quarter within 4 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2023
First posted
Jul 10, 2023
StartActual
Jan 22, 2024
Primary completionEst.
Jun 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05937789
Responsible party
Sponsor
First posted
Jul 10, 2023
Start date
Jan 22, 2024
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 16, 2024

Study contacts

Yin Yi Han, doctor
Contact
noviahan@gmail.com
886972651405

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cholecalciferol

Start the discussion